In addition, several inhibitors for designated PKs, such as ROS tyrosine kinase fusion [14] and serine/threonine-protein kinase B-RAF (BRAF) [15], have been applied to evaluate their efficacy in early clinical trials of CCA with a small sample size. This evidence concerns the gene BRAF and cholangiocarcinoma.